235 related articles for article (PubMed ID: 34992006)
1. Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy.
Laukhtina E; Quhal F; Mori K; Sari Motlagh R; Rajwa P; Yanagisawa T; Mostafaei H; König F; Aydh A; Pradere B; Enikeev D; Karakiewicz PI; Schmidinger M; Shariat SF
Eur Urol Oncol; 2022 Feb; 5(1):120-124. PubMed ID: 34992006
[TBL] [Abstract][Full Text] [Related]
2. Efficacy Assessment of Post-nephrectomy Adjuvant Therapies in Patients with Renal Cell Carcinoma.
Ding K; Yang Z; Zhang D; Sun L
Ann Surg Oncol; 2024 Jun; 31(6):3894-3905. PubMed ID: 38494564
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
Sun M; Marconi L; Eisen T; Escudier B; Giles RH; Haas NB; Harshman LC; Quinn DI; Larkin J; Pal SK; Powles T; Ryan CW; Sternberg CN; Uzzo R; Choueiri TK; Bex A
Eur Urol; 2018 Nov; 74(5):611-620. PubMed ID: 29784193
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis.
Laukhtina E; Quhal F; Mori K; Sari Motlagh R; Pradere B; Schuettfort VM; Mostafaei H; Katayama S; Grossmann NС; Rajwa P; Resch I; Enikeev D; Karakiewicz PI; Shariat SF; Schmidinger M
Urol Oncol; 2021 Nov; 39(11):764-773. PubMed ID: 34400065
[TBL] [Abstract][Full Text] [Related]
5. High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors?
Fallara G; Bandini M; Larcher A; Pederzoli F; Karakiewicz P; Tian Z; Briganti A; Necchi A; Salonia A; Bertini R; Montorsi F; Bex A; Capitanio U
Curr Probl Cancer; 2021 Dec; 45(6):100759. PubMed ID: 34130863
[TBL] [Abstract][Full Text] [Related]
6. 2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2022 Feb; 81(2):134-137. PubMed ID: 34920897
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
[TBL] [Abstract][Full Text] [Related]
8. A network meta-analysis evaluating the efficacy and safety of adjuvant therapy after nephrectomy in renal cell carcinoma.
Guo L; An T; Huang Z; Chong T
BMC Urol; 2024 Mar; 24(1):55. PubMed ID: 38454397
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK; Tomczak P; Park SH; Venugopal B; Ferguson T; Chang YH; Hajek J; Symeonides SN; Lee JL; Sarwar N; Thiery-Vuillemin A; Gross-Goupil M; Mahave M; Haas NB; Sawrycki P; Gurney H; Chevreau C; Melichar B; Kopyltsov E; Alva A; Burke JM; Doshi G; Topart D; Oudard S; Hammers H; Kitamura H; Bedke J; Perini RF; Zhang P; Imai K; Willemann-Rogerio J; Quinn DI; Powles T;
N Engl J Med; 2021 Aug; 385(8):683-694. PubMed ID: 34407342
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial.
Motzer RJ; Russo P; Haas N; Doehn C; Donskov F; Gross-Goupil M; Varlamov S; Kopyltsov E; Lee JL; Lim HY; Melichar B; Zemanova M; Rini B; Choueiri TK; Wood L; Reaume MN; Stenzl A; Chowdhury S; McDermott R; Michael A; Izquierdo M; Aimone P; Zhang H; Sternberg CN;
Eur Urol; 2021 Mar; 79(3):334-338. PubMed ID: 33461782
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab.
Serzan M; Atkins MB
Expert Rev Anticancer Ther; 2022 Jun; 22(6):565-574. PubMed ID: 35483033
[TBL] [Abstract][Full Text] [Related]
12. Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario.
Ciccarese C; Strusi A; Arduini D; Russo P; Palermo G; Foschi N; Racioppi M; Tortora G; Iacovelli R
Cancer Treat Rev; 2023 Apr; 115():102528. PubMed ID: 36905896
[TBL] [Abstract][Full Text] [Related]
13. A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality.
Palumbo C; Mazzone E; Mistretta FA; Knipper S; Perrotte P; Shariat SF; Saad F; Kapoor A; Lattouf JB; Simeone C; Briganti A; Antonelli A; Karakiewicz PI
Clin Genitourin Cancer; 2020 Aug; 18(4):314-321.e1. PubMed ID: 32482565
[TBL] [Abstract][Full Text] [Related]
14. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
Motzer RJ; Haas NB; Donskov F; Gross-Goupil M; Varlamov S; Kopyltsov E; Lee JL; Melichar B; Rini BI; Choueiri TK; Zemanova M; Wood LA; Reaume MN; Stenzl A; Chowdhury S; Lim HY; McDermott R; Michael A; Bao W; Carrasco-Alfonso MJ; Aimone P; Voi M; Doehn C; Russo P; Sternberg CN;
J Clin Oncol; 2017 Dec; 35(35):3916-3923. PubMed ID: 28902533
[TBL] [Abstract][Full Text] [Related]
15. Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis.
Yanagisawa T; Kawada T; Quhal F; Bekku K; Laukhtina E; Rajwa P; von Deimling M; Majdoub M; Chlosta M; Pradere B; Mori K; Kimura T; Schmidinger M; Karakiewicz PI; Shariat SF
World J Urol; 2023 Jul; 41(7):1763-1774. PubMed ID: 37209143
[TBL] [Abstract][Full Text] [Related]
16. Cancer-specific mortality in patients with non-metastatic renal cell carcinoma who have undergone a nephrectomy and are eligible for adjuvant pembrolizumab.
Flammia RS; Hoeh B; Hohenhorst L; Sorce G; Chierigo F; Panunzio A; Tian Z; Saad F; Leonardo C; Briganti A; Antonelli A; Terrone C; Shariat SF; Graefen M; Chun FKH; Montorsi F; Gallucci M; Karakiewicz PI
Semin Oncol; 2022 Apr; 49(2):136-140. PubMed ID: 35610060
[TBL] [Abstract][Full Text] [Related]
17. Could a Risk-adapted Approach Support Shared Decision-making Regarding Eligibility for Adjuvant Pembrolizumab for Patients with Clear Cell Renal Cell Carcinoma at High Risk of Recurrence? A Multicentre Cohort Study.
Campi R; Pecoraro A; Roussel E; Amparore D; Mari A; Montorsi F; Porpiglia F; Albersen M; Capitanio U; Minervini A; Serni S; Bertolo R
Eur Urol Oncol; 2024 Jun; 7(3):323-327. PubMed ID: 37945489
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature.
Bandini M; Smith A; Marchioni M; Pompe RS; Martel TF; Cindolo L; Montorsi F; Shariat SF; Briganti A; Kapoor A; Capitanio U; Karakiewicz PI
Clin Genitourin Cancer; 2018 Jun; 16(3):176-183. PubMed ID: 29449091
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials.
Massari F; Di Nunno V; Mollica V; Graham J; Gatto L; Heng D
Clin Genitourin Cancer; 2019 Apr; 17(2):e339-e344. PubMed ID: 30704796
[TBL] [Abstract][Full Text] [Related]
20. How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most?
Fallara G; Larcher A; Rosiello G; Raggi D; Marandino L; Martini A; Basile G; Colandrea G; Cignoli D; Belladelli F; Re C; Musso G; Cei F; Bertini R; Briganti A; Salonia A; Montorsi F; Necchi A; Capitanio U
World J Urol; 2022 Nov; 40(11):2667-2673. PubMed ID: 36125505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
